Other Events ·
Auna revises full-year 2026 Adjusted EBITDA guidance to broadly stable year over year
AUNAAuna S.A.
Auna S.A. updated its full-year 2026 outlook, maintaining revenue growth expectations in line with earlier guidance due to favorable volume and specialty service trends. However, the company lowered its Adjusted EBITDA forecast from a previously targeted 10% to 14% FX-neutral growth range to broadly stable year-over-year performance. This revision reflects unexpected cost pressures from a specific payor contract in Colombia involving a high incidence of advanced-stage cancer cases within the covered population. Capital expenditures remain guided at approximately 4.0% of consolidated revenue, while free cash flow and leverage are evolving favorably. Auna will provide further details on these implications during its upcoming third-quarter earnings call. The company also hosted an Investor Day to discuss long-term strategy across Mexico, Peru, and Colombia. Auna is a leading integrated healthcare platform in Latin America providing access to high-complexity disease treatment.